F-1/A: NewGenIvf Group Limited Files Amendment to Registration Statement

NewGenIvf Group Limited has filed an amendment to its F-1 registration statement, detailing an offering of Class A Ordinary Shares and Pre-Funded Warrants, alongside disclosures on recent financial performance, strategic investments, and ongoing Nasdaq listing compliance efforts.

Summary

• NewGenIvf Group Limited is offering up to 5,454,545 Class A Ordinary Shares and/or Pre-Funded Warrants, with selling securityholders offering up to 4,364,044 Class A Ordinary Shares.
• The company reported a net income of $9,728,723 for the year ended December 31, 2025, a significant turnaround from a net loss of $(474,101) in 2024.
• Revenue decreased by 13.01% to $4,726,433 in 2025, primarily due to a decline in IVF treatment services.
• Significant operating expenses were incurred in 2025, largely due to professional fees for real estate development in the UAE and increased staff costs.
• The company completed the acquisition of MicroSort Lab Services, LLC and Nodexus Inc. in 2025, recognizing substantial bargain purchase gains.
• NewGenIvf is actively managing Nasdaq listing requirements, having implemented multiple reverse stock splits and regained compliance with the minimum bid price rule.
• The company has engaged in various debt financing activities, including issuing convertible notes and entering into a repurchase and forbearance agreement with JAK Opportunities VI LLC.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as cautiously optimistic, with significant financial restructuring and strategic investments offset by ongoing operational challenges and market uncertainties.

Positives

• Achieved a net income of $9,728,723 in 2025, a significant improvement from a net loss in 2024.
• Successfully acquired MicroSort Lab Services, LLC and Nodexus Inc., recognizing substantial bargain purchase gains of $2,487,835 and $19,166,000 respectively.
• Regained compliance with Nasdaq's minimum bid price rule through reverse stock splits and is working towards maintaining listing requirements.
• Secured significant debt financing through various convertible note issuances and credit line facilities.
• Expanded technological capabilities with the acquisition of MicroSort and Nodexus technologies, potentially enhancing gender selection and genetic disease detection services.

Negatives

• Revenue decreased by 13.01% to $4,726,433 in 2025, primarily due to a decline in IVF treatment services.
• Operating expenses increased significantly by 291.05% in 2025, driven by professional fees for real estate development, increased staff costs, and write-offs.
• The company has a history of not meeting SEC filing deadlines, posing a risk to its reporting compliance.
• The company has multiple outstanding convertible notes totaling $4,353,422 as of December 31, 2025, which could lead to dilution.
• The company has limited insurance coverage for its operations, exposing it to significant uninsured risks.
• The company's real estate development project in the UAE is subject to market volatility and potential oversupply.
• The company's proposed Solana digital asset purchase arrangement with White Lion is novel and subject to extreme volatility and regulatory scrutiny.

Risks

• The company may not be able to continue operating as a going concern due to significant outstanding convertible promissory notes and payment obligations.
• The fertility market is competitive, and failure to compete effectively could materially affect results.
• The company has a limited operating history with its current platform, making future performance prediction difficult.
• The company's rapid business transformation into real estate development and digital asset management involves substantial risks and may not be successful.
• The company's new strategic initiatives may strain management and operational resources.
• The company's real estate development projects are subject to numerous risks that could prevent the realization of projected returns.
• The valuation of acquired assets, such as intellectual property, is complex and subjective and may not be realized.
• The company is reliant on revenue from international clients, which can be affected by global travel conditions and geopolitical events.

Future Outlook

The company plans to use net proceeds for investment in K25.ai, restructuring of debt securities, working capital, manufacturing and deployment of Nodexus machines, and other general corporate purposes. The company intends to retain future earnings and does not expect to pay dividends in the near future.

Management Comments

• NewGenIvf's vision is to provide tailored ARS solutions to fulfill patients dreams of becoming a parent.
• The company plans to offer broad fertility services for fertility tourists across Asia Pacific, continue to invest in laboratories and facilities, increase brand awareness and market share, and expand service reach through acquisitions and partnerships.
• Management believes that its strategic presence in Thailand, Cambodia, and Kyrgyzstan positions it to take advantage of opportunities across Asia-Pacific.
• The company's management believes that the acquisition of MicroSort and Nodexus technologies will enhance its capabilities in gender selection and genetic disease detection.

Industry Context

StockSavvy.ai notes that NewGenIvf operates in the growing Asia-Pacific Assisted Reproductive Services (ARS) market, driven by increasing infertility rates, later maternal ages, and growing social acceptance of ARS. However, the market is also characterized by financial challenges, limited access to treatment, and cultural roadblocks.

Comparison to Industry Standards

• The average cost per IVF cycle by NewGenIvf is around US$7,000 (excluding medication), which is positioned as relatively low compared to the US market.
• The company's implantation rate is reported at 70.9% and miscarriage rates are reduced by 26.6% due to technologies like PGS, though direct industry standard comparisons are not provided in this filing.
• The company's revenue from IVF treatments in 2025 was 82.6% of total revenue, with fertility referral services contributing 17.4%, indicating a shift in revenue mix compared to 2024 where IVF was 100% of revenue.

Corporate Governance

Legal Proceedings

• On April 25, 2025, Wing Fung Alfred Siu and Hei Yue Tina Fong, among others, were arrested in Hong Kong for alleged violations of the Human Reproductive Technology Ordinance (HRTO) related to sex selection and surrogacy advertising. They were released on bail, and no further action has been taken by prosecutors.
• On October 26, 2025, Wing Fung Alfred Siu was served a summons for allegedly violating section 17(2) of the HRTO, prohibiting commercial surrogacy arrangements and advertising surrogacy arrangements. He was granted bail, and faces potential fines and imprisonment if convicted.

Related Party Transactions

• Remuneration paid to directors Wing Fung Alfred Siu and Hei Yue Tina Fong totaled $1,793,103 in 2025, including a bonus of $750,000.
• A service agreement with Harcourt Limited, controlled by Mr. Siu and Ms. Fong, resulted in payments of $230,772 for administrative support in 2025.
• Consulting services for fund raising were provided by Mr. Daniel Siu ($219,045) and Mr. Jaspar Siu ($65,000) in 2025.
• The company acquired a 2% minority equity interest and made deposits for an additional 11% equity interest in PredicXion from Mr. Kong Yiu Cheung, a director and shareholder, with cash and share considerations totaling $2,287,500 and 1,240,741 Class A ordinary shares issued.

Stakeholder Impact

• Shareholders: The offering may dilute existing shareholders' ownership and voting power. The dual-class share structure concentrates significant voting power with Class B shareholders.
• Investors: Investing in this offering involves a high degree of risk, including the potential for substantial losses and the possibility of losing the entire investment.
• Creditors: The company has significant outstanding convertible notes and other debt, which could impact its ability to meet obligations.
• Employees: The company aims to attract and retain qualified personnel, with share incentive plans in place, but faces intense competition for talent.

Next Steps

• Complete the offering of Class A Ordinary Shares and Pre-Funded Warrants.
• Use net proceeds for investment in K25.ai, debt restructuring, working capital, and other corporate purposes.
• Continue to monitor and comply with Nasdaq listing requirements.
• Integrate acquired businesses (MicroSort and Nodexus) and leverage their technologies.
• Pursue strategic acquisitions and partnerships to expand service reach.
• Develop and invest in laboratories and facilities.
• Increase brand awareness and market share in the Asia Pacific ARS market.
• Execute real estate development projects in the UAE.

Key Dates

Recommendation

The company shows signs of recovery with a significant net income in 2025 and successful acquisitions, but faces substantial risks including revenue decline, high operating expenses, ongoing Nasdaq compliance issues, and significant debt. The proposed offering is dilutive and the company's diversification into new, unproven sectors like real estate and digital assets adds considerable uncertainty. A 'hold' recommendation reflects the balance between potential upside from strategic moves and the significant risks that could impede future growth and profitability.

Keywords

Assisted Reproductive Services, IVF Treatment, Fertility Referral Services, MicroSort Technology, Nodexus Technology, Preimplantation Genetic Screening, Nasdaq Listing Compliance, Convertible Notes